Plain-English translation of NCT07205666 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is gathering real-world information about what happens when pregnant or breastfeeding people take eplontersen, a medication that treats a rare heart and nerve disease called transthyretin amyloidosis. Because very few pregnant people have used this medication, doctors want to collect any available cases to learn more about its safety for both mother and baby. This information will help guide medical decisions in the future.
Right now, there is almost no information about how this medication affects pregnancy, breastfeeding, or infant health. This study exists to fill that important gap so that healthcare providers can better counsel patients and make safer treatment decisions.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will not attend in-person visits. Instead, researchers will work with your healthcare provider or use existing medical records to gather information about your pregnancy, health while taking the medication, and your baby's health in the first year of life. The team may contact you or your doctor multiple times to collect or clarify medical information.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
Germany
Enrollment target
~10 participants
Started
November 2025
Primary completion
December 2035
Last updated on clinicaltrials.gov in August 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
AstraZeneca Clinical Study Information Center
AstraZeneca
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.